Comparative Pharmacology
Head-to-head clinical analysis: AMOXAPINE versus CLOMIPRAMINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMOXAPINE versus CLOMIPRAMINE HYDROCHLORIDE.
AMOXAPINE vs CLOMIPRAMINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of serotonin reuptake and, to a lesser extent, norepinephrine reuptake. Also exhibits weak dopamine D2 receptor antagonism and alpha1-adrenergic blockade.
Tricyclic antidepressant that inhibits serotonin and norepinephrine reuptake, with additional anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
200-300 mg/day orally in divided doses, initially 50 mg three times daily; maximum 400 mg/day
Oral, initial 25 mg three times daily; increase gradually to 100-250 mg/day in divided doses; maximum 300 mg/day for severe conditions.
None Documented
None Documented
Parent drug: 8-12 hours; active metabolite (8-hydroxyamoxapine): approximately 30 hours; steady-state achieved in 3-5 days
Clinical Note
moderateAmoxapine + Budesonide
"The therapeutic efficacy of Budesonide can be decreased when used in combination with Amoxapine."
Clinical Note
moderateAmoxapine + Fluticasone furoate
"The therapeutic efficacy of Fluticasone furoate can be decreased when used in combination with Amoxapine."
Clinical Note
moderateAmoxapine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Amoxapine is combined with Fluticasone propionate."
Clinical Note
moderateTerminal elimination half-life of clomipramine is 19-37 hours (mean ~30 hours); active metabolite desmethylclomipramine has half-life of 54-77 hours. Steady-state achieved within 1-2 weeks.
Primarily renal (approximately 60-70% as metabolites, <5% unchanged); minimal fecal elimination (<10%)
Renal: ~60% (as conjugated metabolites and unchanged drug); Fecal: ~30% (biliary excretion); 2-3% excreted unchanged in urine.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant
Amoxapine + Desmopressin
"The risk or severity of adverse effects can be increased when Amoxapine is combined with Desmopressin."